Project Grant R03HL183105
- Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $743,388 on August 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center to investigate the mechanisms by which sleep loss and circadian misalignment induce insulin resistance. The research deliverable consists of two randomized, placebo-controlled trials (RCTs) enrolling 48 healthy adults (24 women)...
- Federal Project Grant Award Summary The University of Utah received a $730,993 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through May 31, 2030. This research project investigates the mechanistic contribution of internal circadian misalignment to cardiometabolic risk associated with sleep loss. The research addresses a significant public health challenge, as over...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $150,104 to the Regents of the University of Colorado (University of Colorado-Denver) on January 26, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The project, titled "Lysine Myristoylation as a Novel Mechanism for Regulating PKA in the Heart," will be completed by December 31, 2028. The research investigates an alternative mechanism to activate protein kinase A (PKA)...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded $169,992 to the University of Colorado-Denver on September 18, 2025, to support a mixed-methods research study titled "Start Strong." This K01 mentored career development award funds research investigating optimal antihypertensive medication initiation strategies and will generate evidence for a future pragmatic trial testing a...
- Federal Grant Award Summary The University of Pittsburgh received a $790,584 Project Grant award dated September 4, 2025, from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). This Phase II trial investigates the optimal duration of overnight naps for night shift workers—specifically public safety workers and healthcare workers—to determine which nap length restores normal blood pressure (BP) dipping patterns while minimizing...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1.099 million Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) to Michigan State University's Henry Ford Health+Michigan State University Health Sciences partnership, effective June 1, 2026, through March 31, 2033. The project, "Precision Circadian Medicine for Shift Workers in the Digital Era," addresses shift work disorder (SWD) among the estimated 20% of the workforce...
- Federal Grant Award Summary Rush University Medical Center received a $783,899 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 5, 2026, with completion expected June 30, 2031. The grant funds a longitudinal research study examining the impact of early elementary school start times on sleep health, learning outcomes, and obesity in young children. The research will enroll 200...
- Federal Project Grant Award Summary The University of Alabama at Birmingham received $788,356 in Project Grant funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 13, 2026, with completion targeted for March 31, 2030. This four-year ancillary study to the Coronary Artery Risk Development in Young Adults (CARDIA) study, titled CARDIA CKMovers (Associations of Movement and Sleep Behaviors Through the...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) awarded a Project Grant of $1,067,898 to the University of Alabama at Birmingham (UAB) effective September 5, 2025, with completion targeted for June 30, 2029. This research initiative investigates circadian mechanisms governing cardiac growth and their relationship to heart failure development, with particular focus on heart failure with...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $234,000 to the University of Colorado-Denver under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a prospective study examining the relationship between directly measured skin pigmentation and pulse oximetry bias. The two-year project (September 1, 2025 – August 31, 2027) addresses a critical gap in medical device validation by objectively measuring skin pigmentation to assess its...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $117,000 Project Grant to The Regents of the University of Colorado (University of Colorado-Denver) effective July 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This proof-of-concept study will evaluate the feasibility and preliminary efficacy of aerobic exercise as a countermeasure to the harmful cardiometabolic effects associated with night shift work. The research addresses a significant public health gap, as approximately one-fourth of the U.S. working population works nontraditional hours and faces increased risk of cardiovascular disease, obesity, and type 2 diabetes due to circadian misalignment. The deliverables include assessment of recruitment process feasibility, optimization of study protocols, staff training, and patient experience improvement in preparation for a future definitive clinical trial. The project will employ a rigorous, well-controlled randomized crossover study utilizing a 6-day simulated shift work inpatient protocol with 8 healthy male and female participants in Aurora, Colorado. Specific research outcomes will measure the effectiveness of guidelines-based aerobic exercise in counteracting cardiometabolic impairments such as endothelial dysfunction, elevated blood pressure, dysglycemia, and decreased insulin sensitivity caused by circadian misalignment. The study is scheduled for completion by June 30, 2028, and will generate evidence to inform whether aerobic exercise represents a viable lifestyle intervention for shift workers to mitigate cardiovascular and metabolic disease risk.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $117.0k | 7/7/26 |